PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older

Community Acquired Pneumonia (CAP) Clinical Trial

Official title:

Low Intervention Study of the Effectiveness Of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Against Vaccine Type Pneumococcal Hospitalised Community Acquired Pneumonia (CAP) in Adults 60 Years and Older Using A Test Negative Design Study in A Well-Defined Area of the South of Madrid Region

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04613375
• Other study ID #: B1851202
• Secondary ID: CIBELES
• Status: Completed
• Start date: March 12, 2021
• Est. completion date: March 24, 2024

Study information

• Verified date: April 2024
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Low interventional, prospective, multicentre, hospital-based study involving adults 60 years of age and older hospitalised with CAP at participating sites.

Description:

PCV13 efficacy for the prevention of vaccine-type community-acquired pneumonia (VT-CAP) and invasive pneumococcal disease (IPD) was established in the Community-acquired Pneumonia Immunization Trial in Adults (CAPITA) aged 65 and older. However, there are still few available real-life effectiveness estimates in adults. The aim of this study is to evaluate the PCV13 vaccine effectiveness (VE) against hospitalised VT-pneumococcal CAP among adults aged ≥60 years in the Region of Madrid (Spain). Determination of the effectiveness of PCV13 to prevent hospitalised vaccine-type (VT)-pneumococcal CAP among adults aged ≥60 years in Madrid will be evaluated using a test-negative design study, overall and among immunocompetent persons only.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1786
• Est. completion date: March 24, 2024
• Est. primary completion date: October 25, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

1. Age =60 years.

2. Evidence of pneumonia within first 48 hours of hospital admission

3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

1. Any patient who develops signs and symptoms of pneumonia after being hospitalized for =48 hours (either at current hospital, another transferring hospital, or a combination of these).

2. Previously enrolled subjects readmitted =14 days after discharge for their study qualifying admission.

3. At the time of enrollment, pneumonia has been excluded as the diagnosis or another diagnosis confirmed.

Related Conditions & MeSH terms

• Community Acquired Pneumonia (CAP)
• Pneumonia

Intervention

Diagnostic Test:
• Urine sample collection
Serotype specific UAD (urinary antigen detection) test
• Saliva collection
Streptococcus pneumonia identification in saliva samples by culture or PCR / RSV identification in saliva samples by PCR

Locations

Country	Name	City	State
Spain	Hospital Universitario Fundación Alcorcón	Alcorcón, Madrid
Spain	Hospital Universitarios De Getafe	Getafe	Madrid
Spain	Hospital Universitario Severo Ochoa	Leganés	Madrid
Spain	Hospital Universitario de Mostoles	Mostoles	Madrid
Spain	Hospital Universitario de Móstoles / Servicio de Oncología Médica	Mostoles
Spain	Hospital Universitario Rey Juan carlos	Móstoles

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vaccine effectiveness (VE)	VE calculated as 1 minus the OR* comparing the odds of having received PCV13 for cases and controls, multiplied by 100, overall and restricted to immunocompetent subjects only.	4 years
Secondary	Proportion of CAP events for each pneumococcal serotype, PCV-13, and 20-valent pneumococcal conjugate vaccine (PCV20) serotypes among all CAP subjects with UAD1/2 testing (overall) and among all CAP subjects with a pneumococcus identified	Distribution of S. pneumoniae serotypes using blood, high-quality respiratory cultures, and a serotype-specific urinary antigen detection (UAD) assay among adults 60 years of age and older with CAP.	4 years
Secondary	Proportion of persons with respiratory pneumococcal carriage among adults 60 years of age and older presenting with CAP	Proportion of CAP events where the pneumococcus was identified from saliva by the conventional culture or the sensitive molecular method of PCR divided by all CAP events where the subject had a valid saliva specimen test result.	4 years
Secondary	Proportion of participants with CAP and SP-CAP with underlying medical conditions	Proportion of CAP subjects with underlying at-risk and high-risk medical conditions, overall and restricted to those with pneumococcus isolated from blood, high-quality respiratory cultures, and a serotype specific urinary antigen detection (UAD) assay	4 years
Secondary	Frequency of antibiotic resistance among Streptococcus pneumoniae isolates by type	Proportion of S. pneumoniae isolates with antibiotic resistance identified by standard of care testing, overall and by resistance type	4 years

External Links

•   To obtain contact information for a study center near you, click here.